C12N 2730/10121
Viruses as such
Official title: Viruses as such, e.g. new isolates, mutants or their genomic sequences
C12N2730/10121 (Viruses as such) appears on 9 US grants and 20 published applications in this corpus.
Search patents in C12N- Granted patents
- 9
- Published applications
- 20
- Assignees
- 28
- Inventors
- 64
- Latest grant
- 18 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2006 | 0 | 1 |
| 2007 | 0 | 1 |
| 2008 | 1 | 0 |
| 2009 | 0 | 0 |
| 2010 | 1 | 0 |
| 2011 | 0 | 0 |
| 2012 | 0 | 0 |
| 2013 | 0 | 1 |
| 2014 | 0 | 0 |
| 2015 | 0 | 1 |
| 2016 | 1 | 2 |
| 2017 | 1 | 1 |
| 2018 | 1 | 0 |
| 2019 | 0 | 2 |
| 2020 | 1 | 0 |
| 2021 | 1 | 2 |
| 2022 | 0 | 1 |
| 2023 | 0 | 2 |
| 2024 | 0 | 3 |
| 2025 | 1 | 0 |
| 2026 | 1 | 3 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Treatment of diseases related to hepatitis B virus18 Aug 2026US 12,709,634 B2Erasmus University Medical Center Rotterdam
- Optimized engineered meganucleases having specificity for a recognition sequence in the Hepatitis B virus genome9 Sep 2025US 12,410,418 B2Precision BioSciences, Inc.
- MHC class I associated hepatitis B peptides7 Dec 2021US 11,191,828 B2Emergex Vaccines Holding Ltd.
- Retro- and lenti-HBV hybrid vectors and constructs6 Oct 2020US 10,793,876 B2Virongy L.L.C.
- MHC class I associated peptides for prevention and treatment of hepatitis B virus infection18 Dec 2018US 10,155,036 B2Emergex Vaccines Holding Ltd.
- Compositions and methods for treating viral infections6 Aug 2026US 2026/0226474 A1The University of Sydney
- Optimized engineered meganucleases having specificity for a recognition sequence in the hepatitis b virus genome16 Jul 2026US 2026/0201354 A1Precision BioSciences, Inc.
- Epigenetic editing tool for targeting hepatitis b virus gene9 Apr 2026US 2026/0097133 A1Epigenic Therapeutics Pte. Ltd.
- Hepatitis b virus (hbv) knockouts24 Oct 2024US 2024/0350665 A1EmendoBio Inc.
- Compositions and methods for treating hepatitis b virus infection5 Sep 2024US 2024/0294914 A1Beam Therapeutics Inc.
Most cited
By later US patents
- Hepatitis-B viral variants with reduced susceptibility to nucleoside analogs and uses thereof10US 7,422,848 B2Innogenetics N. V. · 2008
- Variants of hepatitis B virus resistant against some nucleoside analogues, but sensitive to others, and uses thereof6US 7,807,437 B2Justus-Liebig-Universitaet Gissen · 2010
- Primate model from the family cercopithecidae infected by a HBV strain of human genotype2US 9,247,720 B2Hospices Civils De Lyon · 2016